Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mepolizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Mepolizumab. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-003162-25 Sponsor Protocol Number: MEA116841 Start Date*: 2015-02-26
    Sponsor Name:GlaxoSmithKline Research Ltd
    Full Title: Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in...
    Medical condition: Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10018701 Granulomatous disease LLT
    21.1 100000004866 10072580 Granulomatous polyangiitis LLT
    21.0 100000004864 10014956 Eosinophilic granuloma LLT
    20.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    21.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002014-52 Sponsor Protocol Number: FOOTSTEP Start Date*: 2019-01-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB
    Medical condition: severe eosinophilic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001152-29 Sponsor Protocol Number: 201956 Start Date*: 2015-07-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) CZ (Completed) EE (Completed) SK (Completed) GR (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000184-32 Sponsor Protocol Number: 205203 Start Date*: 2017-09-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622
    Medical condition: Hypereosinophilic syndrome (HES)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) PL (Completed) Outside EU/EEA IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-002473-19 Sponsor Protocol Number: PNEU-ASTHMA-02 Start Date*: 2018-11-13
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: A MULTICENTER PRAGMATIC TRIAL IN BELGIUM
    Medical condition: Adult patients (at least 18yrs-old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001832-77 Sponsor Protocol Number: D3253C00001 Start Date*: 2019-12-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic...
    Medical condition: Eosinophilic Granulomatosis with Polyangiitis (EGPA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-006074-10 Sponsor Protocol Number: MEE103219 Start Date*: 2006-06-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/k...
    Medical condition: Eosinophilic oesophagitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002361-32 Sponsor Protocol Number: 201810 Start Date*: 2016-04-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic a...
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) RO (Ongoing) FR (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000838-39 Sponsor Protocol Number: MHE104317 Start Date*: 2007-10-11
    Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd
    Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
    Medical condition: Hypereosinophilic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022510-11 Sponsor Protocol Number: MEA114092 Start Date*: 2011-02-23
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with ele...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001643-51 Sponsor Protocol Number: MEA115666 Start Date*: 2012-09-17
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial.
    Medical condition: Subjects with severe, refractory asthma and a history of eosinophilic inflammation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004255-70 Sponsor Protocol Number: 205687 Start Date*: 2017-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa...
    Medical condition: Treatment of nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002405-19 Sponsor Protocol Number: 204958 Start Date*: 2017-01-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002666-76 Sponsor Protocol Number: 200363 Start Date*: 2015-06-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000314-54 Sponsor Protocol Number: 201312 Start Date*: 2014-04-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
    Medical condition: Subjects with Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) NL (Completed) ES (Completed) GB (Completed) BE (Completed) CZ (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002513-27 Sponsor Protocol Number: 200862 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003318-10 Sponsor Protocol Number: D20180135 Start Date*: 2021-08-05
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized...
    Medical condition: Patients with a diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) with newly-diagnosed disease or with a relapsing disease at the time of screening
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10078117 Eosinophilic granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001832-36 Sponsor Protocol Number: 204959 Start Date*: 2017-05-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Stu...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001831-10 Sponsor Protocol Number: 205667 Start Date*: 2017-02-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma ...
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001644-21 Sponsor Protocol Number: MEA115661 Start Date*: 2013-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials.
    Medical condition: Subjects with Severe Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:20:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA